The AVENIO family of next-generation sequencing (NGS) oncology assays comprises three liquid biopsy assays and three new corresponding tissue assays with matched panel content. New AVENIO Tumor Tissue Analysis Kits, together with AVENIO ctDNA Analysis Kits, offer a uniquely versatile solution for comprehensive genomic profiling, longitudinal monitoring and concordance analysis of solid tumors from tissue and plasma samples.

Features and Benefits of AVENIO NGS Oncology Assays

  • Flexibility to switch between tissue and plasma to support a variety of research applications
  • Exactly-matched tissue and ctDNA panels (same genes, gene regions and hybrid-capture workflow) for true concordance 
  • All four mutation classes (SNVs, indels, fusions and CNVs) in a single DNA workflow with exceptional sensitivity and specificity*
  • A streamlined, end-to-end workflow from extraction to analysis and reporting in 5 days
  • Includes reagents for DNA extraction, library preparation and target enrichment, as well as bioinformatics and software required to analyze sequencing data and generate reports

All four mutation classes in a single DNA workflow

Potential research applications

AVENIO Kits contain gene panels with biomarkers relevant to clinical cancer research over the course of disease evolution.

AVENIO Tumor Tissue Analysis Kits

Three NGS pan-cancer assays for comprehensive genomic profiling of DNA in formalin-fixed paraffin-embedded (FFPE) tissue samples

Learn More

AVENIO ctDNA Analysis Kits

Three NGS pan-cancer liquid biopsy assays for non-invasive profiling and monitoring of cell-free DNA derived from solid tumors

Learn More

*Data on file.

Contact Us

Contact your local Roche sales representative for more information.